Multifocal giant cell tumor of the carpus: Unusual presentation. Case report and review of the literature

INTRODUCTION AND IMPORTANCE

Giant cell tumors (GCTs) of bone in the carpus are rare. Carpal GCTs are usually solitary lesions; multifocal involvement is exceptional. These lesions have a higher risk of local recurrence after intralesional curettage than those in other body areas.

CASE PRESENTATION

We present a case of a 28-year-old male with a six-month history of a palpable mass in the dorsal aspect of the left wrist. Physical examination revealed a 2 cm, mildly tender mass. Magnetic resonance revealed a large intermediate signal lesion involving completely hamate bone and the distal portion of the triquetrum. Histological examination confirmed a giant cell tumor of the carpus. The patient underwent en-bloc resection of the hamate bone extending to the distal part of the pyramidal. The defect was reconstructed using polymethylmethacrylate cement (PMMA), and intercarpal arthrodesis with the capitate was achieved. Follow-up at 18 months revealed a good clinical evolution, wrist range of motion of 30° of extension, 30° of flexion, and 10° of ulnar and radial deviation without evidence of tumoral recurrence.

CLINICAL DISCUSSION

The current literature suggests a high incidence of local recurrence in carpal GCT, so wide excision with carpal arthrodesis is recommended, especially in Campanacci III and multifocal involvement.

CONCLUSION

Carpal GCT is exceptional, mainly affecting the hamate, capitate, and scaphoid. Most literature supports wide excision of carpal GCT owing to the high recurrence rate with intralesional procedures.

Complete tumor necrosis after neoadjuvant chemotherapy defines good responders in patients with Ewing sarcoma

BACKGROUND

Survival in patients who have Ewing sarcoma is correlated with postchemotherapy response (tumor necrosis). This treatment response has been categorized as the response rate, similar to what has been used in osteosarcoma. There is controversy regarding whether this is appropriate or whether it should be a dichotomy of complete versus incomplete response, given how important a complete response is for in overall survival of patients with Ewing sarcoma. The purpose of this study was to evaluate the impact that the amount of chemotherapy-induced necrosis has on (1) overall survival, (2) local recurrence-free survival, (3) metastasis-free survival, and (4) event-free survival in patients with Ewing sarcoma.

METHODS

In total, 427 patients who had Ewing sarcoma or tumors in the Ewing sarcoma family and received treatment with preoperative chemotherapy and surgery at 10 international institutions were included. Multivariate Cox proportional-hazards analyses were used to assess the associations between tumor necrosis and all four outcomes while controlling for clinical factors identified in bivariate analysis, including age, tumor volume, location, surgical margins, metastatic disease at presentation, and preoperative radiotherapy.

RESULTS

Patients who had a complete (100%) tumor response to chemotherapy had increased overall survival (hazard ratio [HR], 0.26; 95% CI, 0.14-0.48; p < .01), recurrence-free survival (HR, 0.40; 95% CI, 0.20-0.82; p = .01), metastasis-free survival (HR, 0.27; 95% CI, 0.15-0.46; p ≤ .01), and event-free survival (HR, 0.26; 95% CI, 0.16-0.41; p ≤ .01) compared with patients who had a partial (0%-99%) response.

CONCLUSIONS

Complete tumor necrosis should be the index parameter to grade response to treatment as satisfactory in patients with Ewing sarcoma. Any viable tumor in these patients after neoadjuvant treatment should be of oncologic concern. These findings can affect the design of new clinical trials and the risk-stratified application of conventional or novel treatments.

Bone Allograft Prosthesis Composite to Revise a Failed Massive Allo-Prosthesis: Case Report and 10 Years of Follow-Up

An 18-year-old male patient with a high-grade osteosarcoma was initially treated with resection and reconstruction using an osteochondral allograft. The allograft collapsed after five years, and thus a revision with a constrained knee prosthesis was performed. After one year, the implant failed due to a fracture, requiring another revision with a new allo-prosthetic composite. The long-term results were satisfactory.

Allo-prosthetic composites may offer good long-term results after sarcoma resection. The failure of a massive bone allograft does not preclude the use of another allograft to maintain the bone stock and preserve the function.

Biologic osteosynthesis in the treatment of benign and malignant bone tumors

BACKGROUND AND OBJECTIVES

Mechanical augmentation with metal implants in the treatment of bone tumors limits magnetic resonance imaging and computerized tomography scan imaging due to the scattering effect. In addition, modulus of elasticity differences may cause chronic pain. We present a surgical technique in which cortical allografts are used as plates. This is a two-center experience focusing on functional and radiographic outcomes and complications.

METHODS

Under IRB approval, we performed a retrospective patient review. Demographics, treatment indications, tumor characteristics, and complications were collected. Radiographic studies were reviewed to determine the time to osseous incorporation. The last follow-up functional evaluation included the Musculoskeletal Tumor Society (MSTS) score, the Karnofsky scale, and Eastern Cooperative Oncology Group (ECOG).

RESULTS

Thirty patients, seventeen female and thirteen male, 16-year-old in average were included. The most common diagnoses were the humeral aneurysmal bone cyst and unicameral bone cyst. The Median follow-up was 6 years. Cortical allograft incorporation median time was 8.8 months whereas allograft void bone incorporation was 3 months. The average time to full weight-bearing without impact activity was 3.1 months. The most common complication was symptomatic hardware. Other complications included a superficial infection successfully treated with antibiotics, a temporary radial nerve neuropraxia, and an allograft fracture requiring revision surgery. Most patients had an MSTS score higher than 90 (excellent). Patients with malignant tumors had ECOG of 0 and a Karnofsky score of 100.

CONCLUSION

Biological osteosynthesis is a bone preserving and effective modality for mechanical augmentation with excellent functional results and low complication rates.